Navidea Biopharmaceuticals Inc Stock Nyse
Equities
US63937X1037
Biotechnology & Medical Research
Financials (USD)
Sales 2021 | 532K | Sales 2022 | 65.65K | Capitalization | 6.78M |
---|---|---|---|---|---|
Net income 2021 | -11M | Net income 2022 | -15M | EV / Sales 2021 | 50.2 x |
Net cash position 2021 | 3.48M | Net Debt 2022 | 440K | EV / Sales 2022 | 110 x |
P/E ratio 2021 |
-2.5
x | P/E ratio 2022 |
-0.38
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 64.11% |
Managers | Title | Age | Since |
---|---|---|---|
Craig Dais
DFI | Director of Finance/CFO | 58 | 23-07-27 |
Michael Blue
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Richard McFerron
LAW | General Counsel | - | 22-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Joshua Wilson
BRD | Director/Board Member | 47 | 22-09-29 |
John Scott
BRD | Director/Board Member | 69 | 21-07-07 |
Jill Stefanelli
BRD | Director/Board Member | 46 | 23-05-31 |
1st Jan change | Capi. | |
---|---|---|
+1.87% | 42.11B | |
+48.83% | 40.08B | |
+7.68% | 40B | |
-10.82% | 26.87B | |
+7.84% | 24.58B | |
-23.15% | 18.44B | |
+2.58% | 11.94B | |
+29.92% | 11.66B | |
+7.27% | 11.01B |